posted
hopefully we can find the loan confirmation before the PR just like the last one...I think the loan will be here soon...Burg's supposedly on Vacation until Wednesday...I have a feeling they surprise us again with something later this week or early next week...hope I'm right.......
Posts: 291 | From: NJ | Registered: Jun 2006
| IP: Logged |
posted
just got back into town, yep looks oversold again. looks like its gearing for anothewr run to .04 with news
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
posted
isnt this going to completely take off if/when it gets approved in USA after the orphan program? anyone have a timeline on when fda could approve this?
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
I truly believe the July 26 PR was so chock full of good stuff that it deserves a closer look... just my opinions here, but here is our last PR in black, my interpretation/comments in brown
Xechem International, Inc. (OTC BB: XKEM) announced today that response to the first limited sales and distribution of NICOSAN(TM), its new product for the prophylactic management of Sickle Cell Disease (SCD), by its subsidiary, Xechem Pharmaceuticals Nigeria, Ltd. (Xechem Nigeria), has been far greater than anticipated. We expected a significant demand, however even that expectation has been exceeded. Xechem Nigeria has broken ground for a new state-of-the-art commercial scale production facility and accelerated the facility's construction schedule. We of course knew there is a huge desire for the solution that Nicosan brings to those who suffer, and therefore obtained the Nexim loan in advance of the launch so that we could (upon approval of the sale of the drug) get a head start in establishing the larger production plant and manufacture the required quantities at the earliest date possible. We did not do this earlier because we were not sure of the time-line for approval of Nicosan. Xechem Nigeria, which received regulatory approval for NICOSAN(TM), its first major breakthrough "Natural Herbal Drug," on July 3rd, 2006 from the National Agency for Food and Drug Administration and Control of Nigeria (NAFDAC), has been producing the drug in limited quantities at its pilot scale facility in Abuja, Nigeria. This would be the 50000 to 100000 client capacity that you all know about.
Xechem Nigeria's new commercial scale facility will have capacity to meet the demand of Nigeria and other African countries. Nigeria alone has 4 million sickle cell disease patients. As investors in our company, we believe you have the capacity to figure out what this means in the way of revenue projection. There are 4M in Nigeria, another 8M +/- in the balance of Africa.The new facility will also be able to supply the drug for the clinical trials in the United States and the European Union. Yes, we very much intend to follow through with the clinical trials abroad, and this too will be PR’d – perhaps in six months or so.
NICOSAN(TM) was launched by the President of Nigeria, His Excellency Chief Olusegun Obasanjo on July 6th, 2006 at SHESTCO Complex. Immediately after the launch ceremony Xechem Nigeria has started direct sales of NICOSAN(TM) in Abuja, the Federal Capital Territory of Nigeria. Yes, the launch was a big deal. It has been many years in the making, and has had several roadblocks as those of you who have been invested or researched for the last five years well know. But we are there now, and yes we are producing and selling in limited quantities as we gear up with staffing requirements, arrange the construction schedule (yes, even ahead of the 8.2M loan PR – ahem, you do all know the money supply is being finalized –no?)
The drug is taken through one-a-day capsules which, once started, must be taken daily by the patient. The current price for a months supply for Adults is established at N 3,000 Naira (approx. US $23) and for Pediatrics at N 2,400 Naira (approx. US $1, respectively. Xechem is also accepting mail orders for the drug from other States within Nigeria. Alright, still need help with that math? Ok, average of $20 per month x 12 months x well, lets do all of Africa since we will be able to manufacture and distribute that much in. say, two years … ok x 12M SCD sufferers who will be blessed to receive this natural miracle drug, … ok this is a large number … yes, pretty close to $3B annual revenue. Don’t get too excited here … this is after two years- maybe longer. By August 2007, please be more realistic and assume we can effectively service only Nigeria’s 4M SCD population which will bring us our first exciting cash-flow of just shy of $1B. And yes, all revenue is of course recurring since our drug is a treatment, not a cure. Remember that our current O/S count is about 1.5M and our A/S remains at 1.95M. We expect both of these numbers to remain static.
The financing for this first phase of construction was supplied by Nigerian Export-Import (NEXIM) Bank, which loaned Xechem Nigeria N150 Million Naira (US$1.2 million) in June of this year. Xechem estimates that the expanded facility will be fully operational within 9 months. Yes, fully operational, and while we are building this, our new staff will be establishing the best methods we can find as relates to distribution of this superb product throughout Nigeria, and of course the challenges with revenue collection.
Dr. Ramesh Pandey, Chairman and CEO of the Xechem Companies said, "This is a very exciting time for Xechem and one that has been more than four years in the making. Getting NICOSAN(TM) approved for the prophylactic management of Sickle Cell Disease (SCD) was a major milestone which changes Xechem from a research and development company to a full scale business venture with NICOSAN(TM) to market. Plain and simple but profound! While we will retain our R & D capacities, we are indeed now entering new territory with our new manufacturing capacity and a proven huge market of unfortunate SCD clients for whom we finally have relief.
"This also required the construction of a full scale production facility, on which we have now broken ground This plant will meet all the current Good Manufacturing Practices (cGMP) guidelines, the first facility in Nigeria to do so. Some of you may not know, but our Dr. Pandey has been personally instrumental in the establishment of the international herbal source cGMP guidelines. We are grateful to NEXIM Bank for the loan and their early support for this project. This will help ensure the completion of our expanded facility in the shortest possible timeframe. HuH? Read the last two sentences again and then ask if the 8.2M loan is not approved. If you still do not think the loan PR will be huge news, then you will just have to wait for the PR for the new plant commissioning next March. Meantime, just don’t be caught on the sidelines around the time other PR’s to be issued pop up. If you have done your DD, you know what these are. Xechem is very proud to be the leader in bringing NICOSAN(TM) for Sickle Cell sufferers first in Nigerian market which will be followed throughout the African continent and the world."
Posts: 6008 | From: phoenix az | Registered: Mar 2005
| IP: Logged |
posted
great post bond, looks like this just needs to get on the radar again. this still has a lot of life to it imo
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
quote:Originally posted by cactus33: isnt this going to completely take off if/when it gets approved in USA after the orphan program? anyone have a timeline on when fda could approve this?
US trials won't begin until after the new factory is producing in around 9 months.
Posts: 101 | From: Mansfield, TX | Registered: Jul 2006
| IP: Logged |
posted
just jumped +.005 in the last hour. anyone know anything about this? the PR coming out?
Posts: 1307 | From: Pittsburgh, PA | Registered: Jun 2006
| IP: Logged |